Sirnaomics AGM: Anchoring Recovery, Charting Long-Term Value with Six Strategies

2026.06.24

June 23, 2026 – Sirnaomics (2257.HK) held its Annual General Meeting today, primarily in a virtual format. The management team comprehensively reviewed key accomplishments over the past year, candidly assessed areas for improvement, and laid out a systematic plan for the next phase of core strategies. The meeting sent a clear signal of the Company’s unwavering commitment to transparent governance and a sharp focus on value creation.

I. Reshaping the Communication Mechanism and Deepening Transparent Dialogue

At the outset, management announced a significant change: this AGM will be the last to be held predominantly online. Going forward, Sirnaomics will comprehensively reform its investor communication approach, strongly encouraging shareholders to attend meetings in person and engage directly with management and the core team through in-depth, face-to-face interactions. This change is designed to further elevate corporate transparency, strengthen investor relations, and reinforce a top-down cultural foundation of openness and compliance — putting “sunshine governance” into concrete practice.

II. Threefold Gratitude: To Trust, Dedication, and Perseverance

Management extended heartfelt thanks to shareholders, employees, and the Board of Directors:

· To shareholders, for their steadfast trust and unwavering support amid market pressures.

· To all employees, for their extraordinary commitment and personal sacrifice, investing extra hours and persevering at their posts.

· To the Board, for working in lockstep with management throughout the year, precisely steering the Company’s strategy, and safeguarding the broader development landscape.

III. Three Core Achievements Solidifying the Foundation for Recovery

Over the past year, the Company delivered three pivotal results:

1. Comprehensive cost reduction and efficiency enhancement – Non-core expenditures were streamlined, and the cash flow structure was meaningfully optimized.

2. Strategic investment from Bloomage Biotechnology – The successful introduction of Bloomage Biotechnology as a strategic shareholder has paved the way for pipeline commercialization.

3. Institutionalization of “transparent operations” – A core operating principle has been formally established, strengthening internal controls and compliance, and building a robust sunshine governance system.

IV. Six Strategies Defining the Year’s Key Priorities

Looking ahead to the new fiscal year, the Company has defined six core work directions and is committed to achieving measurable breakthroughs in critical areas.

1. Sustain cost optimization: Under the leadership of Mr. Xie; fully disclosed in financial reports to improve operational efficiency.

2. Focus on core R&D: Prioritize small nucleic acid oncology pipeline; develop non-oncology projects via external cooperation to verify PNP & GalAhead™ platform versatility.

3. Recruit strategic shareholders: Attract investors with geographic, industrial and scientific synergy.

4. Accelerate BD development: Fill the gap of no substantial BD deals last year; target at least one valuable industrial partnership this year.

5. Deepen FDA & CDE communication (H2 priority): Finalize executable STP705 skin cancer development roadmap with FDA; expand U.S. pipelines to China and launch new domestic clinical programs.

6.Strengthen IP moat: Multiple new patents to be granted, consolidate long-term technological competitiveness.

Outlook

In closing, management underscored that Sirnaomics’ core strengths remain clear: a proprietary and differentiated small nucleic acid delivery technology platform, high-value clinical pipelines, and an increasingly ingrained internal culture of sunshine compliance and control. Moving forward, with a united workforce, the enduring backing of shareholders, and a clearly executed strategy, the Company is fully confident in capturing structural industry opportunities and continuing to generate long-term shareholder value. Taking this AGM as a fresh starting point, Sirnaomics will advance toward a new phase of high-quality development through actions that are more transparent, more focused, and more pragmatic.

About Sirnaomics

Sirnaomics Ltd.(HK: 2257), known as Asia's "First RNAi Therapeutics Stock," is a clinical-stage global biopharmaceutical company specializing in RNA interference technology. Utilizing its dual core technology platforms and diverse pipeline, the company is at the forefront of developing RNAi therapies to drive industry growth.

Sirnaomics has two proprietary delivery platforms:

Polypeptide Nanoparticle (PNP) Platform: An extrahepatic delivery platform enabling precise targeting of tissues such as skin, adipose tissue, and muscle.
GalAhead™ Delivery Platform: A liver-targeted delivery system with clear IP and long-acting administration capabilities.

The company is also an industry leader with its innovative linker-free, dual-target RNAi technology. Sirnaomics' robust pipeline addresses oncology, local fat reduction, medical aesthetics, and cardiovascular diseases, with multiple products in clinical trials. Beyond its internal development, Sirnaomics embraces an open-collaboration strategy, integrating its technology platforms to support the broader industry and benefit patients worldwide.